pipeline-prospector-insert-v1
X

Find Novel Oncology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Universite de Montreal

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Medigene AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 29, 2020

            Details:

            Medigene will test a range of patented TSA targets provided by UdeM, and will get an exclusive and worldwide license to produce and sell T-cell receptors against up to five of these novel cancer antigens.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GDC-0570

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ningbo NewBay Medical Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            Details:

            Ningbo NewBay Medical Technology has been granted the exclusive global rights to further develop and commercialize GDC-0570.

            Cardiff University

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T cells clone

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ervaxx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 24, 2020

            Details:

            The new collaboration will support a multi-year research program at Cardiff University focusing on the discovery and characterization of T-cells and TCRs reactive to cancer-specific antigens and ligands.

            Skysong Innovations

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SBI-183

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Sapphire Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 22, 2020

            Details:

            SI, the intellectual property management company for Arizona State University, licensed the Patents, Technical Information and Materials to Sapphire on behalf of SI and Mayo Clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabinoids

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2020

            Details:

            Findings suggest use of cannabinoid-based drugs to treat diseases in which there is an overexpression of A3AR including cancer, autoimmune, inflammatory and metabolic diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SNP-7/8a

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2020

            Details:

            The groundbreaking peptide-based personalized cancer vaccine was shown to more efficiently induce T-cell responses against tumor neoantigens compared to traditional vaccines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): T cell based therapy

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: $897.5 million Upfront Cash: $50.0 million

            Deal Type: Agreement January 14, 2020

            Details:

            Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived allogeneic T-cell platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vγ9Vδ2 T cells based antibodies,V?9V?2 T cells based antibodies

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: ProBioGen AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 14, 2020

            Details:

            Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a γδ T-cell engaging bispecific antibody format.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IOV-3001

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Iovance Biotherapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 12, 2020

            Details:

            Iovance Biotherapeutics will use TALEN® Technology from cellectis to develop gene-edited TIL.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Alta Partners

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 10, 2020

            Details:

            Financing will used to discover and develop new small molecule therapies targeting acquired resistance in oncology.

            PharmaCompass